Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Summit Therapeutics Inc.

NASDAQ: SMMT · Life Sciences · 7 alerts · CIK 1599298

Share price
$11.82Close, Nov 16
Market cap
$9.45B
Shares outstanding
799.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Summit Therapeutics Inc. filings on SEC EDGAR ↗

5:23 PM ET 8-K
Capital Raise

Summit Therapeutics Capital Raise

Summit Therapeutics Inc. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 for the potential issuance of common stock. The filing includes a legal opinion from Baker & Hostetler LLP regarding the legality of the shares being offered.

6:05 AM ET 8-K
Capital Raise

Summit Therapeutics Capital Raise of $2B

Summit Therapeutics entered into a securities purchase agreement with AstraZeneca for a $2.0 billion private placement of newly designated Class A Convertible Preferred Stock. The preferred shares are priced at a common stock equivalent of $18.3561 per share and will be used to support the development of ivonescimab, including new clinical collaborations with AstraZeneca's oncology portfolio.

Value
$2B
Counterparty
AstraZeneca Holdings B.V.

“This significant investment, as well as the collaboration, is a powerful validation of the potential of ivonescimab. We are proud to welcome AstraZeneca as a strategic investor as we continue to work with purposeful urgency to make a significant difference for patients with cancer by improving outcomes.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“The developments announced today with AstraZeneca open an exciting new chapter in the advancement of ivonescimab. With a growing body of evidence supporting ivonescimab’s differentiated PD-1 / VEGF bispecific approach, we look forward to further broadening the development plan of ivonescimab and initiating new clinical trials exploring the potential to combine ivonescimab with promising novel anti-cancer compounds, including ADCs, to bring together complementary approaches to tumor-cell killing, antitumor immunity, and the tumor microenvironment.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
8:45 AM ET 8-K
Clinical Trial Data

Summit Therapeutics Clinical Trial Data

Summit Therapeutics announced updated overall survival (OS) results from its global Phase III HARMONi trial of ivonescimab in patients with EGFR-mutated non-small cell lung cancer. The updated June 2026 analysis showed a favorable OS hazard ratio of 0.76 in the global population, demonstrating consistent efficacy across both Western and Asian patient subgroups. No new safety signals were observed, reinforcing the potential of ivonescimab as a treatment option following progression on EGFR-targeted therapy.

Counterparty
Akeso Inc.
8:38 AM ET 8-K
Clinical Trial Data

Summit Therapeutics Clinical Trial Data

Summit Therapeutics' partner Akeso presented updated Phase III HARMONi-2 trial data showing ivonescimab monotherapy significantly improved overall survival compared to pembrolizumab in PD-L1-positive advanced NSCLC. Ivonescimab reduced the risk of death by 27% (HR 0.73) and improved median overall survival by 8.2 months (30.8 months vs 22.6 months).

Counterparty
Akeso Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.